SENS - Senseonics: Positive Catalysts Negative Fundamentals

• Senseonics received FDA approval earlier this year for its 180-day continuous glucose monitoring system.
• Management expects sales to pick up in the second half of this year, along with the rollout of products in the U.S. and Europe.
• Despite product developments and plenty of operating expenses, sales growth is relatively sluggish.
• The market appears to be quite upbeat about Senseonics, as it continues to trade at more than 25x projected sales.

For further details see: